Form 4: ANI Pharma SVP Sells $1.7M in Stock

ANI Pharmaceuticals' SVP of Corporate Development & Strategy, Chad Gassert, sold 20,000 shares of common stock for approximately $1.74 million under a pre-arranged trading plan.

Summary

• Chad Gassert, SVP of Corporate Development & Strategy at ANI Pharmaceuticals Inc. (ANIP), reported a sale of common stock.
• The transaction involved the disposition of 20,000 shares of ANIP common stock.
• The shares were sold on August 15, 2025, at a weighted average price of $86.97 per share, with prices ranging from $86.54 to $88.05.
• The total value of the shares sold is approximately $1,739,400.
• This transaction was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following the transaction, Chad Gassert directly holds 73,615 shares of common stock.
• Additionally, 173,226 shares are held indirectly by Chali Properties LLC, over which Mr. Gassert holds voting and dispositive power.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While insider selling can be perceived negatively, the fact that it was executed under a Rule 10b5-1 plan mitigates concerns about opportunistic selling, indicating a pre-planned financial management decision rather than a reaction to new, negative company information.

Positives

• The sale was conducted under a Rule 10b5-1(c) plan, indicating it was pre-scheduled and not based on immediate, non-public information, which mitigates concerns about opportunistic insider selling.
• The reporting person retains a significant beneficial ownership of 246,841 shares (73,615 direct + 173,226 indirect) after the sale, demonstrating continued alignment with shareholder interests.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived by the market as a slight negative signal, as it reduces the direct equity stake of a senior executive.

Risks

• Market perception of insider selling could lead to short-term negative sentiment, despite the sale being pre-planned under a Rule 10b5-1 plan.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report and does not provide broader industry context or trends. It reflects an individual executive's pre-planned stock disposition within the pharmaceutical sector.

Corporate Governance

Related Party Transactions

• 173,226 shares are held indirectly by Chali Properties LLC, over which the reporting person, Chad Gassert, holds voting and dispositive power. This constitutes a related party holding.

Stakeholder Impact

• Shareholders: The sale reduces the direct ownership stake of a key executive, which could be interpreted as a slight reduction in alignment, though mitigated by the Rule 10b5-1 plan and retained holdings.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

A single Form 4 filing, especially one indicating a pre-planned sale under a Rule 10b5-1 plan, typically does not provide sufficient information to warrant a strong buy or sell recommendation. The sale reduces insider ownership but is a scheduled event, not necessarily indicative of a change in fundamental outlook. Investors should consider this in the broader context of the company's financial performance and strategic initiatives.

Keywords

ANI Pharmaceuticals, ANIP, Insider Trading, Form 4, Stock Sale, Chad Gassert, Rule 10b5-1, Corporate Development, Strategy